Drug Trial Radar · NCT04890873
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 17, 2019
Primary completion
Jul 3, 2023
Study completion Jul 3, 2023
Sponsor
- Lead sponsor
- ERX PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
Conditions
- Obesity
Interventions
ERX1000Drug
ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
PlaceboDrug
A suspension containing magnesium hydroxide carbonate in polysorbate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)Time frame: Day 1 up to end of study (Day 10)
- Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalitiesTime frame: Screening (Day -28) up to end of study (Day 10)
- Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -2), Days 1, 3 and 10
- Part A (Single Dose Group A9): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10
- Part A (Single Dose Group A9): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -1), Days 6 and 10
- Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37
- Part B (Multiple Dose Group B5): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37
- Part B (Multiple Dose Group B5): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -2), Days 30, 33 and 37
- Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 8, 10, 15, 17, 22, 25, 29, 34 and End of Study (Day 41)
- Part B (Multiple Dose Group B6): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 25, 27, 29, 34, 38 and End of Study (Day 41)
- Part B (Multiple Dose Group B6): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -2), Days 34, 38 and End of Study (Day 41)
- Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs)Time frame: Day 1 up to end of study (For Group B5, Day 37 and for Group B6, Day 41)
- Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalitiesTime frame: Screening (Day -28), Check-in (Day-2), Days 7, 14, 21, 28, 34 and End of Study (Day 41)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Labcorp Clinical Research Unit Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.